Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent colorectal peritoneal metastases

被引:0
|
作者
Cashin, Peter Harald [1 ]
Asplund, Dan [2 ,6 ]
Lindskog, Elinor Bexe [2 ]
Ghanipour, Lana [1 ]
Syk, Ingvar [3 ]
Graf, Wilhelm [1 ]
Nilsson, Per J. [4 ,5 ]
Palmer, Gabriella Jansson [4 ,5 ]
机构
[1] Uppsala Univ Hosp, Uppsala, Sweden
[2] Sahlgrens Univ Hosp, Dept Surg, Reg Vastra Gotaland, Gothenburg, Sweden
[3] Skanes Univ Hosp, Malmo, Sweden
[4] Karolinska Univ Hosp, Stockholm, Sweden
[5] Karolinska Inst, Stockholm, Sweden
[6] Univ Gothenburg, Inst Clin Sci, Sahlgrenska Acad, Dept Surg, Gothenburg, Sweden
关键词
Colorectal cancer; Peritoneal metastases; Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Relapse treatment; Systemic chemotherapy; SYSTEMIC CHEMOTHERAPY; CARCINOMATOSIS; MULTICENTER; PROGNOSIS; CANCERS;
D O I
10.1016/j.sopen.2024.05.018
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Secondary treatment of recurrent colorectal peritoneal metastases after previous cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is poorly investigated. Objectives: To evaluate the overall survival outcome of secondary (repeat) CRS + HIPEC compared to palliative treatment in recurrent peritoneal disease. Methods: Patients with colorectal peritoneal metastases treated with an index CRS + HIPEC and subsequently having recurrent peritoneal disease were identified from the prospective Swedish national HIPEC registry. Patients were divided into interventional group (secondary CRS + HIPEC) or palliative group. Multivariable logistic regression, propensity-score matching, and survival outcomes were calculated. Results: Among 575 patients who underwent complete CRS between 2010 and 2021, 208 (36 %) were diagnosed with a subsequent recurrent peritoneal disease. Forty-two patients (20 %) were offered secondary CRS + HIPEC. Propensity-score matching of secondary interventional cases with palliative cases succeeded in 88 % (n = 37) in which female sex, lower peritoneal cancer index at index surgery, longer disease-free interval, and absence of extra-peritoneal metastases were identified as the most relevant matching covariates. Median OS from date of recurrence was 38 months (95%CI 30-58) in the interventional group and 19 months (95%CI: 15-24) in the palliative group (HR 0.35 95%CI: 0.20-0.63, p = 0.0004). Sensitivity analyses confirmed the results. As reference, the median OS from index CRS + HIPEC in the whole colorectal registry (n = 575) was 41 months (95%CI: 38-45). Conclusion: After matching for relevant factors, the hazard ratio for death was significantly reduced in patients who were offered a secondary CRS + HIPEC procedure for recurrent peritoneal disease. Selection bias is inherent, but survival outcomes were comparable to those achieved after the initial procedure.
引用
收藏
页码:45 / 50
页数:6
相关论文
共 50 条
  • [1] Iterative Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Peritoneal Metastases
    Sommariva, Antonio
    Tonello, Marco
    Cona, Camilla
    Pilati, Pierluigi
    Rossi, Carlo Riccardo
    ANTICANCER RESEARCH, 2018, 38 (09) : 5521 - 5524
  • [2] Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastases
    Chua, Terence C.
    Quinn, Liam E.
    Zhao, Jing
    Morris, David L.
    JOURNAL OF SURGICAL ONCOLOGY, 2013, 108 (02) : 81 - 88
  • [3] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases of colorectal origin
    Kok, N. E. M.
    de Hingh, I. H. J. T.
    BRITISH JOURNAL OF SURGERY, 2017, 104 (04) : 313 - 315
  • [4] Recurrent Peritoneal Metastases after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer
    Koenigsrainer, I.
    Struller, F.
    Zieker, D.
    Koenigsrainer, A.
    Beckert, S.
    ZENTRALBLATT FUR CHIRURGIE, 2015, 140 (06): : 607 - 609
  • [5] Role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of Colorectal Peritoneal Metastases
    Shah, Rupen
    Gangi, Alexandra
    CLINICS IN COLON AND RECTAL SURGERY, 2024, 37 (02) : 90 - 95
  • [6] Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Systematic Review
    Parikh, Manasi S.
    Johnson, Paul
    Romanes, Jonathan Paul
    Freitag, Harvey E.
    Spring, Mary E.
    Garcia-Henriquez, Norbert
    Monson, John R. T.
    DISEASES OF THE COLON & RECTUM, 2022, 65 (01) : 16 - 26
  • [7] Direct surgery with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastases
    Ljunggren, Malin
    Nordenvall, Caroline
    Palmer, Gabriella
    EJSO, 2021, 47 (11): : 2865 - 2872
  • [8] Simultaneous cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, and hepatectomy for colorectal peritoneal and liver metastases
    Lau, Ming
    Lo, Oswens Siu Hung
    Li, Yu Yin
    Au, Kin Pan
    Chan, Albert C. Y.
    Foo, Dominic C. C.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 517 - 517
  • [9] The importance of synchronicity in the management of colorectal peritoneal metastases with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Jolene Si Min Wong
    Grace Hwei Ching Tan
    Claramae Shulyn Chia
    Johnny Ong
    Wai Yee Ng
    Melissa Ching Ching Teo
    World Journal of Surgical Oncology, 18
  • [10] The importance of synchronicity in the management of colorectal peritoneal metastases with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Wong, Jolene Si Min
    Tan, Grace Hwei Ching
    Chia, Claramae Shulyn
    Ong, Johnny
    Ng, Wai Yee
    Teo, Melissa Ching Ching
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2020, 18 (01)